COST COMPARISON OF LINEZOLID VERSUS VANCOMYCIN FOR TREATMENT OF NOSOCOMIAL PNEUMONIA AND COMPLICATED SKIN AND SOFT TISSUE INFECTION CAUSED BY MRSA IN QUEBEC

被引：0
|
作者：
Pettigrew, M. [1 ]
Thirion, D. J. [2 ]
Libman, M. [3 ]
Zanotti, G. [4 ]
机构：
[1] Symbiose, Montreal, PQ, Canada
[2] Univ Montreal, Montreal, PQ, Canada
[3] McGill Univ, Ctr Hlth, Montreal, PQ, Canada
[4] Pfizer Canada Inc, Kirkland, PQ, Canada
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 03期
关键词：
D O I：
10.1016/j.jval.2011.02.648
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A116 / A116
页数：1
相关论文
共 50 条
  • [21] Clindamycin Plus Vancomycin Versus Linezolid for Treatment of Necrotizing Soft Tissue Infection
    Dorazio, Joshua
    Chiappelli, Abby L.
    Shields, Ryan K.
    Tsai, Y. Vivian
    Skinker, Peyton
    Nabozny, Michael J.
    Bauza, Graciela
    Forsythe, Raquel
    Rosengart, Matthew R.
    Gunn, Scott R.
    Marini, Rachel
    Clarke, Lloyd
    Falcione, Bonnie
    Ludwig, Justin
    McCreary, Erin K.
    OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (06):
  • [22] Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus
    Itani, Kamal M. F.
    Dryden, Matthew S.
    Bhattacharyya, Helen
    Kunkel, Mark J.
    Baruch, Alice M.
    Weigelt, John A.
    AMERICAN JOURNAL OF SURGERY, 2010, 199 (06): : 804 - 816
  • [23] Positive Phase IV results suggest higher rates of success for linezolid versus vancomycin for the treatment of MRSA nosocomial pneumonia
    不详
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2010, 8 (12) : 1330 - 1330
  • [24] Cost-effectiveness of linezolid versus vancomycin in the treatment of nosocomial pneumonia suspected to be caused by methicillin-resistant Staphylococcus aureus in Spain
    Leon, C.
    Gomez, Mateos J. M.
    Catala, R.
    Vazquez, M. J.
    Alvarez, Rocha L.
    Najera, M. D.
    Rubio-Terres, C.
    Garcia, M.
    Escudero, Lopez-Cepero E.
    VALUE IN HEALTH, 2007, 10 (06) : A439 - A440
  • [25] Evaluation of a novel vancomycin versus linezolid ICU cycling protocol in documented MRSA nosocomial pneumonia.
    Vyas, Nikunj
    Slain, Douglas
    Keller, Lisa
    Sarwari, Arif R.
    PHARMACOTHERAPY, 2014, 34 (10): : E246 - E246
  • [26] What is the place of linezolid in the treatment of methicillin-resistant Staphylococcus aureus nosocomial pneumonia and complicated skin and soft tissue infections in Europe?
    Dumitrescu, O.
    Lina, G.
    CLINICAL MICROBIOLOGY AND INFECTION, 2014, 20 : 1 - 2
  • [27] Decision analytic model evaluating the cost-effectiveness of linezolid versus vancomycin in methicillin-resistant staphylococcus aureus complicated skin and soft tissue infection
    Bounthavong, M.
    Okamoto, M. P.
    Hsu, D.
    VALUE IN HEALTH, 2008, 11 (03) : A97 - A97
  • [28] Linezolid versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections
    Barry J. Hartman
    Current Infectious Disease Reports, 2001, 3 (5) : 448 - 449
  • [29] Linezolid versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections
    Barry J. Hartman
    Current Infectious Disease Reports, 2007, 3 (5) : 448 - 449
  • [30] Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus
    Sharpe, JN
    Shively, EH
    Polk, HC
    AMERICAN JOURNAL OF SURGERY, 2005, 189 (04): : 425 - 428
12345